Julian Little has been a Professor in the School of Epidemiology and Public Health (Director 2006-2016) at the University of Ottawa since 2004. He currently holds a Distinguished Research Chair in Chronic Disease Epidemiology and Control, is a Visiting Professor at Shanghai Jiao Tong University School of Medicine (2017-2020) and is an IUSS-Ferrara 1391 Copernicus Visiting Scientist, University of Ferrara (2018-2019). His PhD, from Aberdeen University, was on problems of ascertainment of congenital anomalies. Subsequently, he worked for the EUROCAT Central Registry in Brussels (Belgium), as a lecturer in epidemiology in Nottingham University, as an epidemiologist in the International Agency for Research on Cancer in Lyon, and as Professor of Epidemiology at Aberdeen University, during which he spent a sabbatical year at the Office of Genomics and Disease Prevention, CDC, Atlanta. His current research includes work on:
 Congenital anomalies, specifically (a) the effects of B-group vitamins on congenital anomalies and other chronic diseases; (b) completeness of ascertainment; (c) maternal gene-environment effects on orofacial clefts and congenital heart disease; and (d) prenatal screening;
 Psychosis and affective psychosis, specifically (a) within-week variation in in-hospital outcomes for patients with psychosis and affective psychosis; (b) trajectories of hospitalizations; and (c) the development and testing of a multifaceted intervention including physical activity aimed at improving physical health and quality of life;
 Knowledge synthesis and public health, co-PI of the Ottawa Evidence Review and Synthesis Centre, funded by the Public Health Agency of Canada to support development of preventive healthcare guidelines by the Canadian Task Force on Preventive Health Care. There are ongoing projects on screening for esophageal cancer, depression and hypertension, prenatal screening, tobacco cessation and polypharmacy;
 Head & Neck Conditions, specifically (a) oral and genital HPV infection in female partners of men with HPV-related head and neck cancer; (b) the frequency of, and risk factors for, persistent oral oncogenic HPV infection oral HPV and hearing impairment; (c) the outcomes of different managements for sensorineural hearing loss; (d) use of remote audio-verbal therapy after cochlear implant; and (e) analysis of audiometric tests using an iPad App.